Ergomed PLC (LON:ERGO) had its target price upped by research analysts at N+1 Singer from GBX 265 ($3.31) to GBX 275 ($3.44) in a research note issued to investors on Monday. The brokerage presently has a “buy” rating on the stock. N+1 Singer’s target price points to a potential upside of 113.18% from the company’s previous close.
Other equities analysts also recently issued reports about the stock. Stifel Nicolaus reiterated a “buy” rating and set a GBX 271 ($3.39) price objective on shares of Ergomed PLC in a research note on Tuesday, November 1st. Numis Securities Ltd reiterated a “buy” rating and set a GBX 267 ($3.34) price objective on shares of Ergomed PLC in a research note on Tuesday, November 1st.
Ergomed PLC (LON:ERGO) remained flat at GBX 129.00 during midday trading on Monday. The company had a trading volume of 577 shares. The stock’s market cap is GBX 40.14 million. Ergomed PLC has a 52 week low of GBX 117.00 and a 52 week high of GBX 172.00. The company’s 50-day moving average is GBX 125.22 and its 200-day moving average is GBX 125.77.